Spero Therapeutics (SPRO) Competitors $0.69 +0.01 (+0.90%) As of 01:30 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SPRO vs. ACRS, ADCT, LRMR, EDIT, GLSI, TARA, SCPH, LYEL, TNXP, and FATEShould you be buying Spero Therapeutics stock or one of its competitors? The main competitors of Spero Therapeutics include Aclaris Therapeutics (ACRS), ADC Therapeutics (ADCT), Larimar Therapeutics (LRMR), Editas Medicine (EDIT), Greenwich LifeSciences (GLSI), Protara Therapeutics (TARA), scPharmaceuticals (SCPH), Lyell Immunopharma (LYEL), Tonix Pharmaceuticals (TNXP), and Fate Therapeutics (FATE). These companies are all part of the "pharmaceutical products" industry. Spero Therapeutics vs. Aclaris Therapeutics ADC Therapeutics Larimar Therapeutics Editas Medicine Greenwich LifeSciences Protara Therapeutics scPharmaceuticals Lyell Immunopharma Tonix Pharmaceuticals Fate Therapeutics Spero Therapeutics (NASDAQ:SPRO) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations, community ranking and institutional ownership. Do analysts recommend SPRO or ACRS? Spero Therapeutics currently has a consensus target price of $5.00, indicating a potential upside of 609.22%. Aclaris Therapeutics has a consensus target price of $10.00, indicating a potential upside of 684.31%. Given Aclaris Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aclaris Therapeutics is more favorable than Spero Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spero Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50Aclaris Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Which has higher earnings and valuation, SPRO or ACRS? Spero Therapeutics has higher revenue and earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpero Therapeutics$28.30M1.39$22.81M-$1.28-0.55Aclaris Therapeutics$17.78M7.77-$88.48M-$1.39-0.92 Which has more volatility & risk, SPRO or ACRS? Spero Therapeutics has a beta of 0.23, meaning that its share price is 77% less volatile than the S&P 500. Comparatively, Aclaris Therapeutics has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500. Does the media refer more to SPRO or ACRS? In the previous week, Aclaris Therapeutics had 10 more articles in the media than Spero Therapeutics. MarketBeat recorded 11 mentions for Aclaris Therapeutics and 1 mentions for Spero Therapeutics. Aclaris Therapeutics' average media sentiment score of 1.25 beat Spero Therapeutics' score of 0.00 indicating that Aclaris Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spero Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aclaris Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of SPRO or ACRS? 25.6% of Spero Therapeutics shares are held by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are held by institutional investors. 4.5% of Spero Therapeutics shares are held by company insiders. Comparatively, 6.4% of Aclaris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community favor SPRO or ACRS? Aclaris Therapeutics received 181 more outperform votes than Spero Therapeutics when rated by MarketBeat users. However, 69.67% of users gave Spero Therapeutics an outperform vote while only 66.78% of users gave Aclaris Therapeutics an outperform vote. CompanyUnderperformOutperformSpero TherapeuticsOutperform Votes20969.67% Underperform Votes9130.33% Aclaris TherapeuticsOutperform Votes39066.78% Underperform Votes19433.22% Is SPRO or ACRS more profitable? Spero Therapeutics has a net margin of 3.30% compared to Aclaris Therapeutics' net margin of -136.65%. Spero Therapeutics' return on equity of 4.03% beat Aclaris Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Spero Therapeutics3.30% 4.03% 2.21% Aclaris Therapeutics -136.65%-40.26%-31.71% SummaryAclaris Therapeutics beats Spero Therapeutics on 11 of the 19 factors compared between the two stocks. Get Spero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRO vs. The Competition Export to ExcelMetricSpero TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$39.42M$6.45B$5.31B$8.42BDividend YieldN/A2.64%5.21%4.10%P/E Ratio10.079.0426.7819.69Price / Sales1.39253.23386.97118.34Price / Cash1.6265.8538.2534.62Price / Book0.356.406.744.50Net Income$22.81M$143.98M$3.23B$248.32M7 Day Performance8.26%1.90%1.49%-0.03%1 Month Performance-3.71%4.01%11.47%12.72%1 Year Performance-53.16%-3.00%16.57%7.38% Spero Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPROSpero Therapeutics4.1207 of 5 stars$0.69+0.9%$5.00+622.5%-54.6%$38.69M$28.30M9.89150Gap DownACRSAclaris Therapeutics2.8743 of 5 stars$1.25-0.8%$10.67+753.3%+9.3%$135.35M$18.72M-2.40100Positive NewsADCTADC Therapeutics2.6735 of 5 stars$1.35+5.9%$7.75+476.2%-47.6%$133.39M$70.84M-0.56310Analyst RevisionLRMRLarimar Therapeutics2.0736 of 5 stars$2.08-1.9%$19.63+843.5%-75.5%$133.18MN/A-1.8130Positive NewsEDITEditas Medicine4.2669 of 5 stars$1.54+6.2%$5.73+271.9%-72.8%$128.91M$32.31M-0.60230GLSIGreenwich LifeSciences1.2042 of 5 stars$9.58+1.6%$39.00+307.1%-28.1%$127.17MN/A-11.973Positive NewsEarnings ReportTARAProtara Therapeutics2.9944 of 5 stars$3.27+0.9%$20.40+523.9%+10.9%$126.15MN/A-1.1630Positive NewsSCPHscPharmaceuticals4.1069 of 5 stars$2.48+1.6%$14.00+464.5%-12.7%$124.70M$36.33M-1.3130Analyst RevisionLYELLyell Immunopharma2.9658 of 5 stars$0.42+5.4%$1.00+137.2%-84.3%$124.52M$61,000.00-0.53270Positive NewsTNXPTonix Pharmaceuticals3.3822 of 5 stars$19.19+1.9%$585.00+2,948.5%-95.2%$123.49M$10.09M0.0050Analyst UpgradeGap UpFATEFate Therapeutics4.3507 of 5 stars$1.07+2.9%$4.60+329.9%-68.4%$122.63M$13.63M-0.65550 Related Companies and Tools Related Companies Aclaris Therapeutics Alternatives ADC Therapeutics Alternatives Larimar Therapeutics Alternatives Editas Medicine Alternatives Greenwich LifeSciences Alternatives Protara Therapeutics Alternatives scPharmaceuticals Alternatives Lyell Immunopharma Alternatives Tonix Pharmaceuticals Alternatives Fate Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SPRO) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredAI Bloodbath Coming on June 1st?If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SPRO Stock Free SPRO Stock Alerts